Nuclear EGFR as a molecular target in cancer
TM Brand, M Iida, N Luthar, MM Starr… - Radiotherapy and …, 2013 - Elsevier
The epidermal growth factor receptor (EGFR) has been one of the most targeted receptors in
the field of oncology. While anti-EGFR inhibitors have demonstrated clinical success in …
the field of oncology. While anti-EGFR inhibitors have demonstrated clinical success in …
[HTML][HTML] Control of cell metabolism by the epidermal growth factor receptor
LA Orofiamma, D Vural, CN Antonescu - Biochimica et Biophysica Acta …, 2022 - Elsevier
The epidermal growth factor receptor (EGFR) triggers the activation of many intracellular
signals that control cell proliferation, growth, survival, migration, and differentiation. Given its …
signals that control cell proliferation, growth, survival, migration, and differentiation. Given its …
Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 …
Fisetin (3, 3', 4', 7-tetrahydroxyflavone), a naturally occurring flavonoid, has been reported to
inhibit proliferation and induce apoptosis in several cancer types. However, its effect on the …
inhibit proliferation and induce apoptosis in several cancer types. However, its effect on the …
Receptor tyrosine kinases in the nucleus
G Carpenter, HJ Liao - Cold Spring Harbor perspectives …, 2013 - cshperspectives.cshlp.org
To date, 18 distinct receptor tyrosine kinases (RTKs) are reported to be trafficked from the
cell surface to the nucleus in response to ligand binding or heterologous agonist exposure …
cell surface to the nucleus in response to ligand binding or heterologous agonist exposure …
NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance
CF Chiu, YW Chang, KT Kuo… - Proceedings of the …, 2016 - National Acad Sciences
Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-
TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors …
TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors …
Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase …
Hepatocellular cell carcinoma (HCC) is one of the most commonly diagnosed cancers
worldwide and in Taiwan. Chemoprevention of cancer with dietary bioactive compounds …
worldwide and in Taiwan. Chemoprevention of cancer with dietary bioactive compounds …
EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4
Posttranslational modifications of histones play fundamental roles in many biological
functions. Specifically, histone H4-K20 methylation is critical for DNA synthesis and repair …
functions. Specifically, histone H4-K20 methylation is critical for DNA synthesis and repair …
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection
The epidermal growth factor receptor (EGFR) plays an important role in tumor progression
and treatment resistance for many types of malignancies including head and neck …
and treatment resistance for many types of malignancies including head and neck …
Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides
Tyrosine 211 (Y211) phosphorylation of proliferation cell nuclear antigen (PCNA) coincides
with pronounced cancer cell proliferation and correlates with poor survival of breast cancer …
with pronounced cancer cell proliferation and correlates with poor survival of breast cancer …
The roles of subcellularly located EGFR in autophagy
H Li, L You, J Xie, H Pan, W Han - Cellular signalling, 2017 - Elsevier
The epidermal growth factor receptor (EGFR) is a well-studied receptor-tyrosine kinase that
serves vital roles in regulation of organ development and cancer progression. EGFR not …
serves vital roles in regulation of organ development and cancer progression. EGFR not …